Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | USP14 | P54578 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34466654 | 0.81 | ALDH1A1 (0.44) | LMNAPOLBRAB9AL3MBTL1 | |
| SCHEMBL5311879 | 0.81 | ALDH1A1 (0.44) | LMNAPOLBRAB9AL3MBTL1 | |
| SCHEMBL334852 | 0.80 | ALDH1A1 (0.36) | L3MBTL1USP14 | |
| SCHEMBL17390238 | 0.79 | — | — | |
| SCHEMBL17390139 | 0.76 | NPC1 (0.32) | — | |
| SCHEMBL20501232 | 0.76 | CA12 (0.33) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7264258 | 0.76 | IDO1 (0.50) | USP14 | |
| SCHEMBL17030654 | 0.76 | IDO1 (0.50) | LMNAL3MBTL1USP14 | |
| SCHEMBL25321100 | 0.75 | CA12 (0.39) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1535653 | 0.75 | TSHR (0.36) | LMNAPOLBATMUSP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945560-B | GPR119 agonists | 卡尔优普公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230061736-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11512065-B2 | GPR119 agonists | KALLYOPE, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| CN-114945560-A | GPR119 agonists | 卡尔优普公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-4041722-A1 | GPR119 AGONISTS | Kallyope, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220153719-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2022-05-19 | — | — | US | disclosed |
| CN-109071488-B | Substituted 1,2, 3-triazoles as NR 2B-selective NMDA modulators | 詹森药业有限公司 | 2021-08-13 | — | — | CN | disclosed |
| WO-2021071837-A1 | GPR119 AGONISTS | KALLYOPE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-08 | — | — | US | disclosed |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-09 | — | — | US | disclosed |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-19 | — | — | US | disclosed |
| WO-2017139428-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | WO | disclosed |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947206-B2 | cGAS antagonist compounds | CGAS, STING1, GLS2 | LMNA 1551/4885POLB 533/4885RAB9A 3358/4885 |
| US-11512065-B2 | GPR119 agonists | GPR119, GLP1R, GCGR | LMNA 4659/4885POLB 4653/4885RAB9A 1074/4885 |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | LMNA 4692/4885POLB 3574/4885RAB9A 3995/4885 |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | LMNA 4692/4885POLB 3574/4885RAB9A 3995/4885 |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | LMNA 4692/4885POLB 3574/4885RAB9A 3995/4885 |
| US-20230061736-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | LMNA 4659/4885POLB 4653/4885RAB9A 1074/4885 |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | LMNA 4692/4885POLB 3574/4885RAB9A 3995/4885 |
| US-20220153719-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | LMNA 4659/4885POLB 4653/4885RAB9A 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.